AU2019273664B2 - Methods for the treatment of psoriatic arthritis - Google Patents

Methods for the treatment of psoriatic arthritis Download PDF

Info

Publication number
AU2019273664B2
AU2019273664B2 AU2019273664A AU2019273664A AU2019273664B2 AU 2019273664 B2 AU2019273664 B2 AU 2019273664B2 AU 2019273664 A AU2019273664 A AU 2019273664A AU 2019273664 A AU2019273664 A AU 2019273664A AU 2019273664 B2 AU2019273664 B2 AU 2019273664B2
Authority
AU
Australia
Prior art keywords
treatment
patient
compound
score
psoriatic arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019273664A
Other languages
English (en)
Other versions
AU2019273664A1 (en
Inventor
Pille HARRISON
Luc MEULENERS
Chantal Thérèse Tasset
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma SpA filed Critical Alfasigma SpA
Publication of AU2019273664A1 publication Critical patent/AU2019273664A1/en
Assigned to ALFASIGMA S.P.A. reassignment ALFASIGMA S.P.A. Request for Assignment Assignors: GALAPAGOS NV
Application granted granted Critical
Publication of AU2019273664B2 publication Critical patent/AU2019273664B2/en
Priority to AU2025202777A priority Critical patent/AU2025202777A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019273664A 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis Active AU2019273664B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202777A AU2025202777A1 (en) 2018-05-24 2025-04-22 Methods for the treatment of psoriatic arthritis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1808575.3A GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits
GB1808575.3 2018-05-24
PCT/EP2019/063283 WO2019224283A1 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202777A Division AU2025202777A1 (en) 2018-05-24 2025-04-22 Methods for the treatment of psoriatic arthritis

Publications (2)

Publication Number Publication Date
AU2019273664A1 AU2019273664A1 (en) 2021-01-21
AU2019273664B2 true AU2019273664B2 (en) 2025-01-23

Family

ID=62812304

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019273664A Active AU2019273664B2 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis
AU2025202777A Pending AU2025202777A1 (en) 2018-05-24 2025-04-22 Methods for the treatment of psoriatic arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202777A Pending AU2025202777A1 (en) 2018-05-24 2025-04-22 Methods for the treatment of psoriatic arthritis

Country Status (9)

Country Link
US (2) US12329758B2 (https=)
EP (1) EP3801548A1 (https=)
JP (3) JP2021524472A (https=)
CN (1) CN112203660B (https=)
AU (2) AU2019273664B2 (https=)
CA (1) CA3101386A1 (https=)
GB (1) GB201808575D0 (https=)
MA (1) MA52738A (https=)
WO (1) WO2019224283A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP4178616A4 (en) * 2020-07-13 2024-07-24 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445911A1 (en) * 2009-06-26 2012-05-02 Galapagos N.V. 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors
WO2013189771A1 (en) * 2012-06-22 2013-12-27 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
WO2015117980A1 (en) * 2014-02-07 2015-08-13 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2016165953A1 (en) * 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of inflammatory disorders
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044722A1 (en) 1999-01-29 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JPWO2004039816A1 (ja) 2002-10-29 2006-03-02 塩野義製薬株式会社 セフェム化合物の無機酸塩の結晶
CA2515190A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
EP1786811A2 (en) 2004-08-18 2007-05-23 Pharmacia & Upjohn Company LLC Triazolopyridine compounds
WO2006038116A2 (en) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010013768A1 (ja) 2008-07-31 2010-02-04 第一三共株式会社 チアゾリジンジオン化合物の結晶及びその製造方法
JP2013049632A (ja) 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
RS64677B1 (sr) 2015-04-13 2023-11-30 Galapagos Nv Metode lečenja kardiovaskularnih poremećaja
PL3595667T3 (pl) * 2017-03-14 2024-03-18 Galapagos Nv Kompozycje farmaceutyczne zawierające inhibitor jak

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445911A1 (en) * 2009-06-26 2012-05-02 Galapagos N.V. 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors
WO2013189771A1 (en) * 2012-06-22 2013-12-27 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
WO2015117980A1 (en) * 2014-02-07 2015-08-13 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2016165953A1 (en) * 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of inflammatory disorders
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBIN-JAGERSCHMIDT, C. et al. "THE JAK1 SELECTIVE INHIBITOR FILGOTINIB REGULATES BOTH ENTHESIS AND COLON INFLAMMATION IN A MOUSE MODEL OF PSORIATIC ARTHRITIS" ANNALS OF THE RHEUMATIC DISEASES, vol. 76, no. Suppl. 2, June 2017, pages 118-119 *

Also Published As

Publication number Publication date
JP7751362B2 (ja) 2025-10-08
EP3801548A1 (en) 2021-04-14
KR20210013168A (ko) 2021-02-03
CN112203660A (zh) 2021-01-08
MA52738A (fr) 2021-04-14
US12329758B2 (en) 2025-06-17
CN112203660B (zh) 2024-12-31
AU2019273664A1 (en) 2021-01-21
US20210299135A1 (en) 2021-09-30
WO2019224283A1 (en) 2019-11-28
JP2025183397A (ja) 2025-12-16
GB201808575D0 (en) 2018-07-11
JP2021524472A (ja) 2021-09-13
JP2024069223A (ja) 2024-05-21
US20260108530A1 (en) 2026-04-23
AU2025202777A1 (en) 2025-05-08
CA3101386A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US11993605B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
AU2025202777A1 (en) Methods for the treatment of psoriatic arthritis
US11512092B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20220251105A1 (en) Methods of treating a mk2-mediated disorder
US20190314382A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
US11780848B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
JP2023542878A (ja) 多発性硬化症を治療するためのｌｏｕ０６４
Baraf et al. LB0002 SAFETY & EFFICACY OF SEL-212 IN PATIENTS WITH GOUT REFRACTORY TO COVENTIONAL TREATMENT: OUTCOMES FROM TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDIES
TW202126329A (zh) 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
JP2022549379A (ja) ウパダシチニブによる脊椎関節炎及び乾癬状態の治療
KR102955500B1 (ko) 건선성 관절염의 치료 방법
Chaplin Janus kinase inhibitors for autoimmune disorders
US12570664B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Hawkins 54 Rheumatoid Arthritis and Osteoarthritis
Zhang et al. Preclinical characterization of the selective Jak1 inhibitor Lw402 for treatment of rheumatoid arthritis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ALFASIGMA S.P.A.

Free format text: FORMER APPLICANT(S): GALAPAGOS NV

FGA Letters patent sealed or granted (standard patent)